▲ +2.07% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Illumina in the last 3 months. The average price target is $323.59, with a high forecast of $400.00 and a low forecast of $280.00. The average price target represents a 2.07% upside from the last price of $317.03.
The current consensus among 17 polled investment analysts is to hold stock in Illumina. This Hold consensus rating has held steady for over two years.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.